AWM
CTKB icon

AE Wealth Management’s Cytek Biosciences CTKB Stock Holding History

AE Wealth Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62K Buy
+14,193
New +$67K ﹤0.01% 1915

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AE Wealth Management's CTKB Position: Q1 2026 in Review

AE Wealth Management opened a new position in Cytek Biosciences (CTKB) in Q1 2026: 14,193 shares worth $62K. The stake represents ﹤0.01% of the portfolio and ranks #1915 among its holdings.

165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • AE Wealth Management held 14,193 shares of Cytek Biosciences worth $62K as of Q1 2026.
  • Cytek Biosciences was a new AE Wealth Management position in Q1 2026.
  • Cytek Biosciences made up ﹤0.01% of AE Wealth Management's portfolio in Q1 2026, its #1915 holding.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on AE Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.